Roquefort Therapeutics (LON:ROQ) Stock Price Down 4.1% – Here’s Why

Roquefort Therapeutics plc (LON:ROQ) shares dropped 4.1% during mid-day trading on Monday . The company traded as low as GBX 3.55 ($0.05) and last traded at GBX 3.55 ($0.05). Approximately 199,496 shares changed hands during mid-day trading, a decline of 35% from the average daily volume of 308,529 shares. The stock had previously closed at GBX 3.70 ($0.05).

Roquefort Therapeutics Price Performance

The company has a market capitalization of £4.58 million, a PE ratio of -370.00 and a beta of 0.05. The firm has a fifty day moving average of GBX 3.69 and a two-hundred day moving average of GBX 4.26. The company has a current ratio of 0.79, a quick ratio of 3.07 and a debt-to-equity ratio of 12.37.

About Roquefort Therapeutics

Roquefort Therapeutics plc, a biotechnology company, engages in the development of medicines for the treatment of cancer. The company's pre-clinical development pipeline comprises Midkine antibodies with significance in vivo efficacy and toxicology studies; Midkine RNA therapeutics with novel anti-cancer gene editing action; Midkine mRNA therapeutics with novel anti-cancer approach; STAT-6 siRNA therapeutics targeting solid tumors with significance in vivo efficacy; and MK cell therapy with direct and NK-mediated anti-cancer action.